Martin Shkreli livestreamed himself violating lifetime pharma ban, FTC says
摘要
美国联邦贸易委员会及七州总检察长指控Martin Shkreli违反2022年起生效的终身制药行业禁令。Shkreli曾因将抗寄生虫药物Daraprim价格从每片17.50美元暴涨至750美元并阻碍仿制药竞争，被判七年监禁。监管机构称其通过交易多家药企股票及在社交媒体直播中讨论该行业，多次公然违规，已请求联邦法官裁定其藐视法庭。
Martin Shkreli—the ex-pharmaceutical executive infamous for illegally hiking the price of a lifesaving anti-parasitic drug by more than 4,000 percent and getting a seven-year prison sentence for the fraudulent scheme he used to do it—has been under a lifetime ban from the pharmaceutical industry since 2022.
However, according to the Federal Trade Commission and the attorneys general of seven states, Shkreli has "flagrantly and repeatedly" violated that ban nearly the entire time—allegedly by trading stock in dozens of drug companies and discussing the industry during livestreams on social media.
On Tuesday, the FTC and the seven states asked a federal judge to hold Shkreli in contempt for the alleged violations. The states include New York, California, Illinois, North Carolina, Ohio, Pennsylvania, and Virginia—the same states that joined the FTC in suing Shkreli in 2020 over the "elaborate anticompetitive scheme" involving the anti-parasitic drug, Daraprim. The scheme raised the price from $17.50 per pill to $750 per pill virtually overnight, while blocking generic competitors from entering the market.
转载信息
评论 (0)
暂无评论，来留下第一条评论吧